dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Prieto-Peña, Diana |
dc.contributor.author | Bernabeu, Pilar |
dc.contributor.author | Vela, Paloma |
dc.contributor.author | Narváez, Javier |
dc.contributor.author | Fernández-López, Jesús C. |
dc.contributor.author | Freire-González, Mercedes |
dc.contributor.author | Solans Laque, Roser |
dc.date.accessioned | 2022-03-31T08:55:53Z |
dc.date.available | 2022-03-31T08:55:53Z |
dc.date.issued | 2021-01 |
dc.identifier.citation | Prieto-Peña D, Bernabeu P, Vela P, Narváez J, Fernández-López JC, Freire-González M, et al. Tocilizumab in refractory Caucasian Takayasu’s arteritis: a multicenter study of 54 patients and literature review: Ther Adv Musculoskelet Dis. 2021 Jan;13:1–12. |
dc.identifier.issn | 1759-7218 |
dc.identifier.uri | https://hdl.handle.net/11351/7285 |
dc.description | Arteritis de Takayasu; Tocilizumab; Teràpia biològica |
dc.description.sponsorship | The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was partially supported by RETICS Programs, RD08/0075 (RIER), RD12/0009/0013 and RD16/0012 from “Instituto de Salud Carlos III” (ISCIII) (Spain). However, this research did not receive any specific grant from funding agencies in the commercial or not-for-profit sectors. |
dc.language.iso | eng |
dc.publisher | SAGE Publications |
dc.relation.ispartofseries | Therapeutic Advances in Musculoskeletal Disease;13 |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Vasculitis - Tractament |
dc.subject | Anticossos monoclonals - Ús terapèutic |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Takayasu Arteritis |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antibodies, Monoclonal, Humanized |
dc.subject.mesh | /therapeutic use |
dc.title | Tocilizumab in refractory Caucasian Takayasu’s arteritis: a multicenter study of 54 patients and literature review |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1177/1759720X211020917 |
dc.subject.decs | arteritis de Takayasu |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | anticuerpos monoclonales humanizados |
dc.subject.decs | /uso terapéutico |
dc.relation.publishversion | https://doi.org/10.1177/1759720X211020917 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Prieto-Peña D] Department of Rheumatology, Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain. [Bernabeu P, Vela P] Department of Rheumatology, Hospital General de Alicante, Alicante, Spain. [Narváez J] Department of Rheumatology, Hospital de Bellvitge, Barcelona, Spain. [Fernández-López JC, Freire-González M] Department of Rheumatology, Complejo H. Universitario de A Coruña, A Coruña, Spain. [Solans-Laqué R] Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 34211589 |
dc.identifier.wos | 000688092300001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |